WASHINGTON, DC (PRWEB) February 27, 2013
Genomics will be at the forefront of the 3rd annual CanLiv Research Symposium, a free event sponsored by the CanLiv Foundation. CanLiv is a nonprofit committed to advancing knowledge, education, research and treatments of rare hepatobiliary cancer (cancers of the bile ducts, gallbladder and liver). Oncology researchers, doctors, patient advocates, foundation experts and others are invited to attend the Friday, April 5 event at ASAE Center for Association Leadership in Washington, D.C.
Dr. Daniel Heller, former Editor-in-Chief of The Journal of Clinical Oncology and Emeritus Professor of Medicine at Abramson Cancer Center, will moderate the Symposium.
Sessions for 2013 include:
Additionally, there will be two moderated roundtable discussions:
“CanLiv has grown tremendously since the last symposium,” said Dr. Melanie Thomas, President of CanLiv and Associate Director of Clinical Investigations at Hollings Cancer Center, Medical University of South Carolina. “The formation of the CanLiv International Hepatobiliary Cancer Research Consortium will be detailed at this year’s event. We hope to continue to expand the Consortium’s reach to enhance collaboration around the globe”
Cancers of the bile duct, gallbladder and liver are often referred to as “orphan” tumors because they have few effective treatment options, there is little public awareness, and very little research funding. Hepatobiliary cancers are relatively uncommon in developed countries, but are major public health problems in much of Asia, sub-Saharan Africa and parts of South America. CanLiv addresses this gap between current and predicted patient needs and available nonsurgical treatment options.
The CanLiv Foundation was created by a group of cancer researchers on several continents who were all struck by the absence of knowledge and shared insights related to hepatobiliary cancers (liver, gallbladder and bile ducts). Since 2007, the organization has formalized a program of research and information sharing, created a patient-focused website and online community with educational materials and more, and brought attention to cancers that affect millions of patients worldwide.